Date: 2012-05-23
Type of information: Services contract
Compound: bioproduction services (antibody humanization, generation of CHO cell lines...)
Company: Selexis (Switzerland) Fusion Antibodies Services (UK)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, has established a partnership with Fusion Antibodies Services that will combine core technologies of the two companies allowing customers to link monoclonal antibody (MAb) humanization programs with the generation of high performing and fully documented CHO cell lines. Customers will be able to seamlessly go from non-human MAbs to clinical candidate generated in a cGMP ready CHO cell line in 8 months. Clinical candidates are selected based on both expression and binding activity from stable CHO pools. Using the antibody humanization and engineering services from Fusion Antibodies, sequenced variable domains of mouse MAbs from a hybridoma cell line are analyzed using bioinformatics. The
complementarity determining regions (CDRs) of the variable domains are identified and incorporated into
human immunoglobulin donor sequences to generate panels of full length heavy and light chain
antibodies. Optimal heavy and light chain pairs are chosen using the Selexis SUREvariant Screening™
platform which allows for the identification of the best antibody based on both activity and expression
level from stable cell pools. This platform utilizes the proprietary Selexis SUREtechnology Platform™ and the Selexis SURECHO-M™ cell line to generate variant panels ranging from several to > 100 stably-expressing
protein variant cell lines, with typical expression levels above 100 mg/L. These variant proteins,
expressed with mammalian modifications, can be assessed for activity. Manufacturing cell lines of the
top candidates can be readily isolated from the stable transfectants.
Financial terms:
Latest news:
